Please assess the completion status of the following clinical trial:

Trial Title: Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed Type 2 Diabetes diagnosis~* Plan to fast during Ramadan~* Treated with a combination of metformin and an Sulfonylurea (SU) for at least 12 weeks and HbA1c ≤8.5% at Visit 1~* Taking a sulfonylurea treatment for less than 3 years prior to Visit 1~* Body mass index (BMI) ≥22 and ≤45 kg/m2 at Visit 1~Exclusion Criteria:~* Pregnant or nursing (lactating) women~* History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.~* Patients who are taking any other anti-diabetes drug (oral or injection) other than metformin and an SU component.~* Inability to comply with the study procedures or medications.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vildagliptin + placebo to Gliclazide (Type: EXPERIMENTAL): Vildagliptin tablets will be given at 50mg twice daily (bid). Placebo to Gliclazide capsules will be given at an equivalent dose to previous sulfonylurea in multiples of 80mg only (80-320 mg/day). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
- Gliclazide + placebo to Vildagliptin (Type: ACTIVE_COMPARATOR): Gliclazide capsules will be given in multiples of 80 mg (80-320 mg/day) at a dose equivalent to previous sulfonylurea dose, unless at the investigator's discretion it could be up-titrated to the next available dose (if HbA1c is higher than 7.5%). Placebo to Vildagliptin tablets will be given at 50mg twice daily (bid). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).